One thing for certain - Astra Zeneca/Oxford University's almost Monty Pythonesque 'announcement' & ensuing revelations have not helped bring forward the date we're going to be let out of Australia.
Bloomberg TV yesterday afternoon showed a graphic which was used as the centrepiece for the segment.
It showed six different countries or Groups (EU) and their advance purchases or commitments for purchasing vaccines from the so-called frontrunners.
Without coming out and saying it, the graph told the story. Astra Zeneca has around 4 to 5x the commitments, if successful, to provide vaccine doses numbering 2-3 billion. If they're seen to be lagging (which Bloomberg detailed they are) then they could miss out on $30 to 50 billion in sales.-
The implication was that AZ was concerned about being left behind so they selectively reported a small proportion of the data from Phase II trial component of a combined Phase II/Phase III trial, and then only detailed an even smaller proportion.
Given the huge negative impact this could have on public confidence on all vaccines - the WHO has come out overnight 'diplomatically' dealing with the 'unusual' situation of AZ.
Meanwhile the UK is reassessing how to rollout one of the competitors;
Exclusive: NHS could receive first deliveries of Pfizer/BioNTech vaccine as soon as 7 December
www.theguardian.com
But the nature of the Pfizer vaccine appears to have forced a rethink of who gets it first. Its composition means it should be moved only a limited number of times, experts believe, and as such it cannot easily be transported by healthcare staff such as GPs to care homes and older people’s private residences.
NHS officials believe that if it is moved more than four times it risks becoming unstable and ineffective. By the time it reaches UK hospitals, it will have been moved twice, from the Pfizer production plant in Belgium to storage hubs in Britain, and from those hubs to hospitals where it can be administered.
&
One NHS official said the differences in the composition and potential availability of the Pfizer and Oxford vaccines meant the initial rollout “could be stop-start”, with a gap of weeks or even months between frontline health personnel and other priority groups being immunised.
The New Scientist provides a good summary of the AZ/Oxford issues.
Doubts have been raised over the positive results released earlier this week by AstraZeneca and the University of Oxford from trials of their coronavirus vaccine. Here's what you need to know
www.newscientist.com
Makes the extension of international border restrictions to March 17 look likely. Perhaps when they were saying they'd look to open up by Easter they meant Easter 2021!